Huge biotech stocks are collectively getting hit in recent days.
BIIB has announced results on 24/10/17, beating top and bottom line expectations but stock still gap down and closed 3.9% down.
Prices fail to break above the top of the trendline measuring from Minute Wave ((a)) and reverse from the 100% fibonacci projection similarly from Minute Wave ((a)).
This is strong evidence of the relevancy of Minute Wave ((a)).
From a technical view, BIIB has seemingly completed a textbook A-B-C consolidation.
The recent high on 18/10/17 appears to be the final consolidation high.
Stock might attempt to retest this high $348.84 before continuing falling.
A successful re-test of this high will bring the stock down to its 24/06/17 low at $205.42.
A break above its recent high $348.84 will invalidate this analysis and imply a more complex consolidation on a larger scale.
BIIB has announced results on 24/10/17, beating top and bottom line expectations but stock still gap down and closed 3.9% down.
Prices fail to break above the top of the trendline measuring from Minute Wave ((a)) and reverse from the 100% fibonacci projection similarly from Minute Wave ((a)).
This is strong evidence of the relevancy of Minute Wave ((a)).
From a technical view, BIIB has seemingly completed a textbook A-B-C consolidation.
The recent high on 18/10/17 appears to be the final consolidation high.
Stock might attempt to retest this high $348.84 before continuing falling.
A successful re-test of this high will bring the stock down to its 24/06/17 low at $205.42.
A break above its recent high $348.84 will invalidate this analysis and imply a more complex consolidation on a larger scale.
註釋
Since the large downside gap on 24/10/17 , prices have been consolidating above the low of the gap down candle. Prices are likely to test the Key Resistance Zone within the next few days.
A failure to break and close above this zone will bring prices down below $300 and less.
Watch for the upside volume as the prices test this zone.
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。